jeudi 3 septembre 2015

Onco Actu du 3 septembre 2015

3.1 Tabac

Switching From Conventional to Electronic Cigarettes Reduced Toxicant Exposure, Even for Dual Users [AACR]

4.2 Dép., diag. & prono. - Génome

Genetic landscape can impact treatment for children with rare, aggressive cancer [University of Michigan]

5. Traitements

Recognising and reducing the risk of chemotherapy extravasation [Cancer World]

5.12 Immunothérapies

Ziopharm tests new approach to engineering CAR-Ts for solid tumors [FierceBiotech]

Some leukemia patients see durable results from Novartis therapy [Reuters]

5.2.1 Pharma - Partenariats

After partnering with Big Pharmas, Incyte bags its own PD-1 drug in $795M deal [FierceBiotech]

5.3 Traitements - FDA, EMA,...

U.S. Food and Drug Administration Accepts Supplemental Biologics License Appliction for Opdivo (nivolumab) in Previously Treated Non-Squamous Non-Small Cell Lung Cancer Patients [BMS]

5.3.4 Traitements - AMM (FDA, EMA)

FDA Approves Pediatric Indication for EMEND® (aprepitant) Capsules in Combination with Other Antiemetic Agents [Merck]

FDA approves new drug treatment for nausea and vomiting from chemotherapy [FDA]

6. Lutte contre les cancers

Two years on for our pioneering TRACERx lung cancer study [Cancer Research UK]

HHS announces proposal to update rules governing research on study participants [HHS]

6.1 Observation

Prophylactic Surgery Nearly Doubles in Men with Breast Cancer [ACS]

Study supports watch-and-wait approach for many prostate cancers [Reuters]

6.11 Patients

Contributing Op-Ed Writer: Was It Cancer? Getting the Diagnosis [NY Times]

6.7 DMP, Big Data & applis

Topol Calls on Healthcare Industry to “Emancipate” Patient Data [Xconomy]